| |
Watch this webinar to hear about the increased importance of accelerating orphan drug development and strategies to help get your drug to clinic faster. View webinar.
|
|
|
Monday, December 5, 2022 | 11am ET / 8am PT The data behind the scenes must match and reflect the physical goods moving through the supply chain. In this webinar, we will discuss the four major components of compliance and how to get the data right to let the product flow. Register now.
|
|
| By Nick Paul Taylor Indivior has snapped up Opiant Pharmaceuticals for an initial $145 million, capitalizing on the fall of the company’s share price throughout the year to add a near-approval nasal formulation of nalmefene to its portfolio. |
|
|
|
By Nick Paul Taylor TriSalus Life Sciences has identified a path to data on its drug delivery device and lead candidate, inking a deal to merge with a special purpose acquisition company and build an anticipated $60 million cash reserve. |
By Nick Paul Taylor Lumos Pharma’s oral treatment for moderate pediatric growth hormone deficiency has failed to match up to Novo Nordisk’s injected drug Norditropin at the interim analysis of a phase 2 trial. But with growth in the Norditropin arm exceeding expectations, Lumos has pinned the blame on baseline imbalances. |
By Nick Paul Taylor PharmaJet has struck an agreement covering the use of its Tropis needle-free injection system in Nigeria, positioning vaccinators to deploy the technology in a project intended to tackle a poliovirus outbreak. |
|
Explore more on the specific needs and challenges for production of low-volume drugs. This article examines commercial packaging and supply challenges and explores potential solutions. View the summary.
|
|
By Fraiser Kansteiner Viatris and Kindeva declared victory over a fourth patent on AZ’s drug-device combo Symbicort, which brought home more than $2.7 billion in sales for the British pharma last year. |
By Nick Paul Taylor New device, new trial, same flop. That is the story at Satsuma Pharmaceuticals, which suffered a second stock-crushing phase 3 bellyflop after tweaks to its migraine nasal drug delivery device failed to yield an asset capable of beating placebo. |
By Andrea Park 2022 is undoubtedly a fraught time in the history of the women’s movement, but it is also an inspiring one, as people from every corner of the globe come together in support of the idea that women deserve equal rights. That double-edged sentiment echoes throughout this year’s list of the 20 fiercest women in life sciences. |
Fierce podcastsDon't miss an episode |
| This week on “The Top Line,” we share some highlights from Fierce Biotech's Cell and Gene Therapy Forum in case you missed it. |
|
|---|
|
|
|
Wednesday, November 30, 2022 | 11am ET / 8am PT In this webinar, we will show how data centricity, digitalization and automation streamlines CMC content authoring and why it is the most viable solution to tackle the associated challenges. Register now.
|
|
| eBookSee how digital therapeutics (DTx) combined with patient engagement software offer a new opportunity for life science organizations (LSOs) to better serve and support patients. Download the guide from Health Catalyst to learn more. Sponsored by: Health Catalyst |
| WhitepaperAccelerating bioproduction towards high performance and scale Sponsored by: Capgemini Americas Inc. |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| |
|
